The Experimental and Developmental Therapeutics (EDT) program of the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) is focused on improving the therapy of cancer through innovative pre-clinical and clinical research. The activities within this program span the range of experimental and developmental therapeutics from initial target discovery to regulatory approval for new treatments. This program identifies new therapeutic targets for cancer, new therapies and approaches directed at these targets, and has the expertise to help translate discoveries. The EDT program facilitates the assessment of novel therapies by fostering collaboration between pre-clinical and clinical researchers ultimately to provide patients with the best possible treatments. Key themes within EDT include: 1) identification of novel therapeutic targets, 2) synthesis and pre-clinical assessment of new compounds directed at specific targets and 3) preclinical assessment of compounds in novel cancer situations. The integration in December 2007 of UTHSCSA's cancer-focused resources with those of the CTRC's Institute for Drug Development (IDD) has allowed a greater emphasis on the efficient translation of preclinical research into eariy phase clinical studies within the EDT program and will allow rapid further Phase 11/111 exploration of promising approaches. The EDT program has 31 scientific members representing 8 departments from the School of Medicine, the Graduate School of Biomedical Sciences, and important components of the CTRC at UTHSCSA including the IDD and the Greehey Children's Cancer Research Institute. EDT program members currently receive $5.55 million (direct costs) annually in peer-reviewed grants from the NCI, NIH, FDA, and Department of Defense. Training is a very important component of the EDT program's activities. Program members train fellows and graduate students in pre-clinical and clinical departments. The IDD's Advanced Oncology/Hematology Drug Development Fellowship is a unique training program for physicians that focuses specifically on the multidisciplinary nature of anti-cancer therapy development. In summary, the EDT program is a highly integrated multidisciplinary collaborative effort between pre-clinical and clinical scientists, all focused on providing newer, better-targeted and more effective treatments for patients with cancer

Public Health Relevance

The Experimental and Developmental Therapeutics (EDT) Program is the keystone of the CTRC at UTHSCSA's effort to develop and test new treatments for cancer. It is a highly integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the prognosis of patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-19
Application #
8320958
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
19
Fiscal Year
2011
Total Cost
$37,070
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:

Showing the most recent 10 out of 989 publications